Moderna's first-quarter revenue for 2023 exceeded Wall Street expectations, reaching $389 million, primarily due to strong international sales of its COVID-19 vaccine. The company has shifted its focus overseas amidst uncertainty in U.S. vaccination policies under Health Secretary Robert F. Kennedy Jr. Despite a challenging domestic market, Moderna is optimistic about stabilizing revenues by 2026, with projections indicating that about half of its revenue will come from the U.S., down from 62% last year. The firm reported a loss per share of $3.40, which was better than analysts' expectations of a $3.96 loss. Looking ahead, Moderna is diversifying its portfolio by developing new vaccines, including a combination COVID-flu vaccine, which has received European approval and is under review in Canada and Australia. The company aims to capture a significant portion of the respiratory vaccines market in Europe, projected to be worth between $1.8 billion and $2 billion.